Heart Rhythm Society
Heart Rhythm Society
May 13, 2016
4 min watch

VIDEO: Expert discusses efficacy of subcutaneous ICD in EFFORTLESS study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — In this video, Lucas V.A. Boersma, MD, PhD, from St. Antonius Hospital, Nieuwegein, Netherlands, discusses data from the EFFORTLESS study of a subcutaneous implantable cardioverter defibrillator, which he presented at the Heart Rhythm Society Annual Scientific Sessions.

At 1-year follow-up, 98% of patients implanted with the device (Emblem S-ICD System, Boston Scientific) were free from device complications, exceeding the FDA’s pre-specified endpoint of 79%, he said.

Other endpoints of interest were an infection rate of 2%, a rate of inappropriate shock from atrial fibrillation or supraventricular tachycardia of 1.5% and an overall 1-year rate of inappropriate shock of 8.1%, he said.

Boersma also said that he and his colleagues observed a 99.5% rate of successful acute conversion testing.

“The S-ICD continues to show that the data are robust, that it saves lives ... with [a] new algorithm we can also avoid T-wave over-sensing, which will ... lower the inappropriate shock rate tremendously in patients,” Boersma said. “I think that the future looks bright for S-ICD.”